PF-04634817
- Generic Name
- PF-04634817
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36F3N5O3
- CAS Number
- 1228111-63-4
- Unique Ingredient Identifier
- 51M3FB9B9E
- Background
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 199
- Registration Number
- NCT01994291
- Locations
- ๐บ๐ธ
Retinal Diagnostic Center, Campbell, California, United States
๐บ๐ธSouthern California Desert Retina Consultants, Palm Desert, California, United States
๐บ๐ธAmerican Institute of Research (Administrative Only), Whittier, California, United States
PF-04634817 Renal Impairment Study
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT01791855
- Locations
- ๐บ๐ธ
Unversity of Miami, Miami, Florida, United States
๐บ๐ธAvail Clinical Research, LLC, DeLand, Florida, United States
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 226
- Registration Number
- NCT01712061
- Locations
- ๐จ๐ฆ
Co-Medica Research Network Inc., Courtice, Ontario, Canada
๐ช๐ธHospital Universitario Vall d'Hebron, Barcelona, Spain
๐บ๐ธClinical Trial Network, Houston, Texas, United States
A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01247883
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01140672
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
First In Human Study Of Increasing Oral Doses Of PF-04634817
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT01098877
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.